Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 3:4:1455321.
doi: 10.3389/fneph.2024.1455321. eCollection 2024.

The Janus-faced nature of complement in hemodialysis: interplay between complement, inflammation, and bioincompatibility unveiling a self-amplifying loop contributing to organ damage

Affiliations

The Janus-faced nature of complement in hemodialysis: interplay between complement, inflammation, and bioincompatibility unveiling a self-amplifying loop contributing to organ damage

Bernard Canaud et al. Front Nephrol. .

Abstract

In hemodialysis (HD), complement activation, bioincompatibility, and inflammation are intricately intertwined. In the 1970s, as HD became a routine therapy, the observation of complement pathway activation and transient leukopenia by cellulosic dialysis membranes triggered the bioincompatibility debate and its clinical relevance. Extensive deliberations have covered definitions, assessment markers, scope, and long-term clinical consequences of membrane-dependent bioincompatibility reactions. While complement pathways' interplay with coagulation and inflammation has been delineated, HD's focus has primarily been on developing more biocompatible membranes using advanced technologies. Recent advances and understanding of the current HD delivery mode (4-hour sessions, thrice weekly) suggest that factors beyond membrane characteristics play a significant role, and a more complex, multifactorial picture of bioincompatibility is emerging. Chronic activation of the complement system and persistent low-grade "uremic inflammation" in chronic kidney disease (CKD) and HD lead to premature inflammaging of the kidney, resembling aging in the general population. Cellular senescence, modulated by complement activation and the uremic milieu, contributes to chronic inflammaging. Additionally, the formation of neutrophil extracellular traps (NETs, process of NETosis) during HD and their biological activity in the interdialytic period can lead to dialysis-induced systemic stress. Thus, complement-inflammation manifestations in HD therapies extend beyond traditional membrane-related bioincompatibility consequences. Recent scientific knowledge is reshaping strategies to mitigate detrimental consequences of bioincompatibility, both technologically and in HD therapy delivery modes, to improve dialysis patient outcomes.

Keywords: biocompatibility; chronic kidney disease; clinical impact; complement; dialysis; inflammation; technology.

PubMed Disclaimer

Conflict of interest statement

Authors RS and SS were employed by company Fresenius SE & Co. KGaA. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The complement system plays a dual role as depicted here: one side represents its essential role ‘Good’ in innate immunity as a defender against foreign invaders, while the other side reflects its harmful contribution ‘Bad’ to complement-mediated diseases, including those associated with hemodialysis.

Similar articles

Cited by

References

    1. Craddock PR, Fehr J, Brigham KL, Kronenberg RS, Jacob HS. Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. New Engl J Of Med. (1977) 296:769–74. doi: 10.1056/NEJM197704072961401 - DOI - PubMed
    1. Craddock PR, Fehr J, Dalmasso A, Brighan K, Jacob H. Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Of Clin Invest. (1977) 59:879–88. doi: 10.1172/JCI108710 - DOI - PMC - PubMed
    1. Chervenick PA. Dialysis, neutropenia, lung dysfunction and complement. (1977). Mass Medical Soc. N Engl J Med. (1977) 296(14):810–2. doi: 10.1056/NEJM197704072961410 - DOI - PubMed
    1. Descamps-Latscha B, Jungers P. New molecular aspects of chronic uraemia and dialysis-related immunocompetent cell activation. Nephrol Dialysis Transplant. (1996) 11:121–4. doi: 10.1093/ndt/11.supp2.121 - DOI - PubMed
    1. Hakim RM, Fearon DT, Lazarus JM, Perzanowski CS. Biocompatibility of dialysis membranes: effects of chronic complement activation. Kidney Int. (1984) 26:194–200. doi: 10.1038/ki.1984.155 - DOI - PubMed

LinkOut - more resources